Misplaced Pages

Branko Kopjar

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
American physician
This biography of a living person relies too much on references to primary sources. Please help by adding secondary or tertiary sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately, especially if potentially libelous or harmful.
Find sources: "Branko Kopjar" – news · newspapers · books · scholar · JSTOR (May 2020) (Learn how and when to remove this message)

Branko Kopjar is a physician and epidemiologist at the University of Washington. He is best known for his contributions in the 1990s to the field of injury prevention and his later work on spine, orthopedic and spinal cord injury research. In addition, he has been published in several top journals in the fields of cardiology, oncology, public health and neurosurgery resulting in a total of more than 500 articles, reports, reviews and abstracts.

Education

He holds an MD (1987) and MS in biostatistics (1991) from the University of Zagreb, and a PhD in health economics and epidemiology from the University of Oslo (1996). Dr. Kopjar also completed a post-graduate Fellowship in Health Services Research.

Career

Prior to joining the University of Washington, Dr. Kopjar served as the Research Director for the Norwegian Foundation for Health Services Research, Head of the Section for Preventive Medicine at the Norwegian Institute of Public Health and as a Ministerial Adviser on health policy to two European governments. He was a participant at the World Injury Conference meetings held in Melbourne, Australia in 1995.

One of his most notable publications include a 2002 sole-authorship which showed that Azithromycin is effective in patients with chronic bronchitis. The findings were published in the Journal of Antimicrobial Chemotherapy.

A year later, he partnered with the Veterans Health Administration to conduct a study on nearly 9,000 patients with coronary heart disease. The research examined how adherence to prescribed statins impacted secondary prevention of coronary heart disease.

Dr. Kopjar was a co-author on a 2013 paper which for the first time showed that surgical decompression is an effective procedure to treat cervical spondylotic myelopathy, a common disease of the spine that can lead to paralysis.

In 2014, Dr. Kopjar was honored with a five-year Distinguished Professorship to the Orthopaedic Department at Chongqing Medical University in Chongqing, P.R. China., a World Health Organization-recognized teaching hospital. During his distinguished professorship in China, Dr. Kopjar was also the program director for the Executive Master of Public Health program at the University of Washington School of Public Health. The MPH program is consistently ranked as one of the top 10 in the United States. Throughout this time, he continued publishing scientific papers across various therapeutic areas. For example, he was a co-author on a 2016 paper which showed that surgical intervention, in combination with radiation and chemotherapy, improves outcomes for patients whose cancer has metastasized to the spinal cord.

From 2012 to 2021 Dr. Kopjar was the Study Director for the world's largest spinal cord injury trial, RISCIS. The project was a randomized double-blinded Phase 3 trial funded by the AO Foundation, United States Department of Defense, Christopher and Dana Reeve Foundation and other organizations. The trial enrolled and administered the drug Riluzole to 193 research subjects within 12 hours of traumatic cervical spinal cord injury. The Principal Investigator for the trial was renowned neurosurgeon Michael Fehlings from the University of Toronto. Other leading spine surgeons that are, or have been, involved in RISCIS include Bizhan Aarabi, Nicholas Theodore and Charles Tator. The trial design was presented by Dr. Kopjar during a meeting of the Seattle Science Foundation in 2017. Interim trial results were presented at the Congress of Neurosurgeons 2018 annual meeting. Partially coinciding with his time on the RISCIS trial, Dr. Kopjar also served as a visiting consultant to the Royal Orthopaedic Hospital, a National Health Service hospital in Northfield, England. Also during this time, in 2018, he was also a study author on a 2018 publication in the Journal of Neurosurgery which led to a label change for i-FACTOR™ Peptide Enhanced Bone Graft.

Since 2020, Dr. Kopjar has served as a consultant to the FDA's Orthopaedic and Rehabilitation Devices panel.

In 2020, Dr. Kopjar, along with Drs. Edward. T Davis and Joseph Pagkalos, published a paper on the effects of bearing surfaces on the survival of cementless and hybrid total hip arthroplasty (THA). The paper was a culmination of a multi-year effort that involved analyzing more than 420,000 primary THAs. Clinicians had for years speculated on the likelihood that bearing surface does in fact impact the long-term patient outcomes. THA is one of the most commonly performed surgical procedures in the world as more than 5% of people will undergo the procedure by the age of 80.

In 2021, Dr. Kopjar was a co-author on a publication in The Lancet Neurology which highlighted the findings of a multi-center, Phase 3 trial that was conducted to research the drug riluzole for the treatment of cervical spondylotic myelopathy.

He has been awarded the John M. Eisenberg Best Paper Award issued by the Agency for Healthcare Research and Quality, and the 2013, 2014, 2015 and 2016 Best Paper or Outstanding Paper Awards issued by the North American Spine Society. He is a member of the North American Spine Society's Performance Measurement Committee and its Outcomes Compendium Task Force.

Dr. Kopjar is a Fellow of the American College of Epidemiology. and of the academy of Translational Medicine.

He is a faculty member in the Master of Health Administration program at the University of Washington, one of the top 10 MHA programs in the United States.

References

  1. ^ "Branko Kopjar - Department of Health Systems and Population Health. Graduate Degree (PHD, MPH, MS, MHA) and Certificate Programs at the University of Washington". Archived from the original on 2020-05-11. Retrieved 2020-05-15.
  2. Neckerman, Kathryn (2004). Social Inequality. Russell Sage Foundation. pp. 252–267. ISBN 1610444205. Archived from the original on July 6, 2024. Retrieved November 4, 2016.
  3. Miller, Rosalie R.; Li, Yu-Fang; Sun, Haili; Kopjar, Branko; Sales, Anne E.; Piñeros, Sandra L.; Fihn, Stephan D. (July 2003). "Underuse of cardioprotective medications in patients prior to acute myocardial infarction". The American Journal of Cardiology. 92 (2): 209–211. doi:10.1016/s0002-9149(03)00541-1. PMID 12860227.
  4. Nater, Anick; Tetreault, Lindsay A.; Kopjar, Branko; Arnold, Paul M.; Dekutoski, Mark B.; Finkelstein, Joel A.; Fisher, Charles G.; France, John C.; Gokaslan, Ziya L.; Rhines, Laurence D.; Rose, Peter S.; Sahgal, Arjun; Schuster, James M.; Vaccaro, Alexander R.; Fehlings, Michael G. (1 September 2018). "Predictive factors of survival in a surgical series of metastatic epidural spinal cord compression and complete external validation of 8 multivariate models of survival in a prospective North American multicenter study". Cancer. 124 (17): 3536–3550. doi:10.1002/cncr.31585. PMID 29975401.
  5. "GrantForward Search Engine | Search for federal grants, foundation grants, and limited submission opportunities". www.grantforward.com. Archived from the original on 2024-01-17. Retrieved 2024-01-17.
  6. "Proceedings of the International Collaborative Effort on Injury Statistics Volume II" (PDF). cdc.gov. Hyattsville, Maryland: Centers for Disease Control and Prevention. September 1996. Archived (PDF) from the original on 10 June 2024. Retrieved 2 July 2024.
  7. Kopjar, B. (1 September 2002). "Azithromycin is effective in patients with chronic bronchitis". Journal of Antimicrobial Chemotherapy. 50 (3): 433–a–434. doi:10.1093/jac/dkf114. PMID 12205072.
  8. Kopjar, Branko; Sales, Anne E.B.; Piñeros, Sandra L.; Sun, Haili; Li, Yu-Fang; Hedeen, Ashley N. (2003). "Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population". The American Journal of Cardiology. 92 (9): 1106–1108. doi:10.1016/j.amjcard.2003.07.008. PMID 14583366. Archived from the original on 2024-07-06. Retrieved 2020-06-05.
  9. "New treatment for 'arthritis of the spine' prevents paralysis". Archived from the original on 2016-12-20. Retrieved 2016-12-10.
  10. "Faculty | UW Executive Master of Public Health Degree - Online & Seattle". Archived from the original on 2016-05-31. Retrieved 2016-05-29.
  11. Chongqing Medical University
  12. "About | UW School of Public Health". Archived from the original on 2016-12-05. Retrieved 2016-12-13.
  13. Fehlings, Michael G.; Nater, Anick; Tetreault, Lindsay; Kopjar, Branko; Arnold, Paul; Dekutoski, Mark; Finkelstein, Joel; Fisher, Charles; France, John; Gokaslan, Ziya; Massicotte, Eric; Rhines, Laurence; Rose, Peter; Sahgal, Arjun; Schuster, James; Vaccaro, Alexander (20 January 2016). "Survival and Clinical Outcomes in Surgically Treated Patients With Metastatic Epidural Spinal Cord Compression: Results of the Prospective Multicenter AOSpine Study". Journal of Clinical Oncology. 34 (3): 268–276. doi:10.1200/JCO.2015.61.9338. PMID 26598751.
  14. NCT01597518
  15. "A Multi-Center, Randomized, Placebo Controlled, Double-Blinded, Trial of Efficacy and Safety of Riluzole in Acute Spinal Cord Injury". 16 April 2021. Archived from the original on 28 June 2022. Retrieved 17 June 2022.
  16. "Trial of Efficacy and Safety of Riluzole in Acute Spinal Cord Injury - Branko Kopjar, MD, MS, PhD". YouTube. 6 September 2017. Archived from the original on 2022-06-17. Retrieved 2022-06-17.
  17. "Efficacy and Safety of Riluzole in Acute Spinal Cord Injury (SCI).Rationale and Design of AOSpine Phase III Multi-center Double Blinded Randomized Controlled Trial. (RISCIS)". 25 March 2018. Archived from the original on 2 July 2022. Retrieved 17 June 2022.
  18. "Additional FDA Approval for Cerapedics i-FACTOR Bone Graft | Orthopedics This Week". 3 December 2019. Archived from the original on 2020-01-19. Retrieved 2020-07-29.
  19. Davis, Edward T.; Pagkalos, Joseph; Kopjar, Branko (2020). "Effect of Bearing Surface on Survival of Cementless and Hybrid Total Hip Arthroplasty". JB & JS Open Access. 5 (2): e0075. doi:10.2106/JBJS.OA.19.00075. PMC 7418917. PMID 33123668.
  20. Maradit Kremers, Hilal; Larson, Dirk R.; Crowson, Cynthia S.; Kremers, Walter K.; Washington, Raynard E.; Steiner, Claudia A.; Jiranek, William A.; Berry, Daniel J. (2 September 2015). "Prevalence of Total Hip and Knee Replacement in the United States". The Journal of Bone and Joint Surgery. American Volume. 97 (17): 1386–1397. doi:10.2106/JBJS.N.01141. PMC 4551172. PMID 26333733.
  21. "The Lancet Neurology, February 2021, Volume 20, Issue 2, Pages 81-160, e2". Archived from the original on 2023-03-14. Retrieved 2021-05-25.
  22. "Table of Contents page: The Spine Journal". Archived from the original on 2016-04-16. Retrieved 2016-12-10.
  23. "Outstanding papers in spine: 3 recipients at NASS". 17 November 2014. Archived from the original on 20 December 2016. Retrieved 29 May 2016.
  24. "Table of Contents page: The Spine Journal". Archived from the original on 2016-04-16. Retrieved 2016-12-10.
  25. "The Spine Journal 2016 Outstanding Paper Awards | NASS Daily News". Archived from the original on 2016-12-20. Retrieved 2016-12-10.
  26. "Branko Kopjar - Profile | North American Spine Society". Archived from the original on 2017-09-21. Retrieved 2017-09-21.
  27. "University of Washington". Archived from the original on 2017-03-31. Retrieved 2016-05-29.
  28. "Faculty | UW MHA - Master of Health Administration – Seattle". Archived from the original on 2024-07-06. Retrieved 2016-12-10.
  29. "Best Health Care Management Programs | Health Care Management Degree | US News". Archived from the original on 2015-03-18. Retrieved 2012-02-01.
Categories: